组合物
By using a mixture of TSHR peptides to inhibit the production of TSHR autoantibodies, the treatment challenge of Graves' disease has been solved, providing an effective alternative treatment. The efficacy was evaluated using animal models, achieving effective treatment and prevention of Graves' disease.
CN107249617BActive Publication Date: 2026-07-17WORG PHARM (ZHEJIANG) CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- WORG PHARM (ZHEJIANG) CO LTD
- Filing Date
- 2015-12-23
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing treatments are ineffective in curing Graves' disease, and there is a lack of effective models for evaluating candidate treatments, resulting in poor treatment outcomes and a high risk of relapse.
Method used
A mixture of two TSHR peptides (KKKYVSIDVTLQQLESHKKK and GLKMFPDLTKVYSTD) is used to inhibit or prevent the production of TSHR autoantibodies in the body, and these peptides are administered to treat and prevent Graves' disease.
Benefits of technology
It significantly reduced the production of TSHR autoantibodies, alleviated or prevented Graves' disease symptoms, provided an effective alternative treatment, and evaluated efficacy using animal models.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN107249617B_ABST
Abstract
本发明提供了一种组合物，其包含以下甲状腺刺激激素受体(TSHR)肽：(i)氨基酸序列KKKKYVSIDVTLQQLESHKKK(SEQ ID NO:1)的全部或部分，或者其一部分，或者与SEQ ID NO:1具有至少60％序列同一性的序列；和(ii)氨基酸序列GLKMFPDLTKVYSTD(SEQ ID NO:2)的全部或部分，或者其一部分，或者与SEQ ID NO:2具有至少60％序列同一性的序列。本发明还涉及此类组合物在预防或抑制格雷夫斯病中活化自身抗体形成中的用途。
Need to check novelty before this filing date? Find Prior Art